Introduction: Although venous thromboembolism (VTE) is a well-known complication of
cancer, predicting and mitigating the risks associated with VTE related to cancer remain a …

Introduction: Khorana score (KS) stratifies patients into low, intermediate, and high risk
groups for venous thromboembolism (VTE). We examined the generalizability of the KS to …

Background: Guidelines suggest the use of the Khorana score to select patients with solid
cancer receiving chemotherapy for thromboprophylaxis to prevent venous thromboembolism …

BACKGROUND: Venous thromboembolism is a well-known complication of malignancy.
The Khorana Risk Score (KRS) utilizes the type of cancer, blood counts, and body mass …

The Khorana score is recommended for guiding primary venous thromboembolism (VTE)
prophylaxis in cancer patients, but its clinical utility overall and across cancer types remains …

Background Oncology guidelines suggest using the Khorana score to select ambulatory
cancer patients receiving chemotherapy for primary venous thromboembolism (VTE) …

Introduction: No method of venous thromboembolism (VTE) risk stratification exists for
hospitalized cancer patients. The Khorana score is a validated tool in outpatients with …

We aimed to evaluate the performance of the Khorana score in predicting venous
thromboembolic events in ambulatory cancer patients. Embase and MEDLINE were …

The risk of venous thromboembolism (VTE) is increased in cancer patients. To improve
prediction of VTE in cancer patients, we performed a prospective and observational cohort …

Introduction: The risk of venous thromboembolism (VTE) is increased in patients with cancer
and contributes to significant morbidity, treatment delays and mortality. The Khorana score is …